LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Search

TransMedics Group Inc

Cerrado

SectorSanidad

129.66 -7.32

Resumen

Variación precio

24h

Actual

Mínimo

128.48

Máximo

136.46

Métricas clave

By Trading Economics

Ingresos

81M

105M

Ventas

17M

161M

P/B

Media del Sector

57.874

66.845

Margen de beneficios

65.551

Empleados

898

EBITDA

-916K

32M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+13.37% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 may 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

422M

5B

Apertura anterior

136.98

Cierre anterior

129.66

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

154 / 351 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

TransMedics Group Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

4 ago 2025, 19:15 UTC

Principales Movimientos del Mercado

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

Comparación entre iguales

Cambio de precio

TransMedics Group Inc previsión

Precio Objetivo

By TipRanks

13.37% repunte

Estimación a 12 Meses

Media 158.8 USD  13.37%

Máximo 190 USD

Mínimo 115 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para TransMedics Group Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

11 ratings

8

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

92.43 / 94.18Soporte y Resistencia

Corto Plazo

Weak Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Weak Bullish Evidence

Sentimiento

By Acuity

154 / 351 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.